Becoming ordinary but still extraordinarily expensive

Many different parts of a healthcare system - finance, pharmacy, medical and social work, to name just a few - need to work together to administer cell and gene therapies because of their inherent complexity and price tags that can run into the millions of dollars for a single dose, notes Carina Dol...

Full description

Saved in:
Bibliographic Details
Published inManaged Healthcare Executive Vol. 34; no. 9; p. 10
Main Author Wehrwein, Peter
Format Trade Publication Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 01.09.2024
Subjects
FDA approval
Gene therapy
Health economics
Pharmaceutical industry
R&D
Research & development
United States > US
Online AccessGet full text

Cover

More Information
Summary:Many different parts of a healthcare system - finance, pharmacy, medical and social work, to name just a few - need to work together to administer cell and gene therapies because of their inherent complexity and price tags that can run into the millions of dollars for a single dose, notes Carina Dolan, Pharm.D., M.S.Pharm., associate vice president, clinical oncology, pharmacoeconomics and market insights at Vizient, a group purchasing organization headquartered in Irving, Texas. According to IQVIA's tally, 114 gene therapy trials were started in 2023, a large majority (88 of 114, or 77%) of which were sponsored by industry. Dolan said 120 health systems, payers and manufacturers attended to discuss the operational and other challenges of implementing cell and gene therapy.
ISSN:1533-9300
2150-7120